iECURE, inc.

iECURE is a clinical-stage gene editing company focused on delivering cures and transforming the lives of patients with devastating liver disorders, utilizing new advancements in genetic medicine. We believe our in vivo gene insertion approach has the potential to restore the function of a dysfunctional gene, regardless of mutation, by inserting a functional copy of that gene to provide durable gene expression and long-term, potentially curative, therapeutic benefit. The company is advancing a pipeline of genetic medicines, led by ECUR-506, an investigational gene editing therapy in clinical development for the treatment of neonatal onset ornithine transcarbamylase (OTC) deficiency. iECURE is proud to be recognized as one of the Philadelphia Business Journal’s “Best Places to Work” for the second year in a row and was named to Fierce Biotech’s “Fierce 15” in 2024. We are headquartered in Blue Bell, PA.